Presentation Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study Presenter: Dean J. Kereiakes October 15, 2020 REGISTER for free or LOG IN to view this content Coronary CAD Pharma Presentation TCT 2020 Disrupt CAD III Dean J. Kereiakes Up Next Presentation The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients Presenter: Roxana Mehran October 15, 2020 More slides + Presentation Featured Clinical Research: (TCT36010) MOTIV BTK Pilot Study – Initial Safety and Performance Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold; Initial Report on First 10 Patients Presenter: Michel Bosiers October 15, 2020 Presentation 1-Year Outcomes of Patients with Residual Physiologic Ischemia After Percutaneous Coronary Intervention: The DEFINE PCI Trial Presenter: Manesh Patel October 15, 2020 We Recommend
Presentation The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients Presenter: Roxana Mehran October 15, 2020
Presentation Featured Clinical Research: (TCT36010) MOTIV BTK Pilot Study – Initial Safety and Performance Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold; Initial Report on First 10 Patients Presenter: Michel Bosiers October 15, 2020
Presentation 1-Year Outcomes of Patients with Residual Physiologic Ischemia After Percutaneous Coronary Intervention: The DEFINE PCI Trial Presenter: Manesh Patel October 15, 2020